Press Release | December 5, 2023
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
Read More
Press Release | November 28, 2023
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
Read More
Press Release | November 20, 2023
Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases
Read More
News | October 25, 2023
A new era in medicine: unraveling the evolution and future of gene therapy
Read More
